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ABSTRACT 5 
5-aminosalicylic acid (5-ASA) is the most widely used drug for the treatment of ulcerative colitis. The 
benefits of targeted delivery of 5-ASA to the large intestine are well known, resulting in reduced 
systemic absorption and increased local concentrations at the disease site. In the present study, a 5-
ASA colon delivery system based on the time-dependent strategy, exploiting the relatively consistent 
small intestinal transit time (SITT), was manufactured and evaluated in vitro as well as in vivo. The 10 
system was obtained by successive spray-coating of an immediate-release tablet core with low-
viscosity HPMC and Eudragit

 L. The enteric film was effective in preventing release during the acidic 
stage of the in vitro test, while the HPMC coating brought about reproducible lag phases prior to 
release in phosphate buffer medium. A γ-scintigraphy investigation pointed out that, following 
administration to fasted and fed volunteers, disintegration of the units never occurred prior to colon 15 
arrival. In all cases, a lag time preceded the appearance of the drug and its N-acetyl metabolite in the 
bloodstream, which was found to correlate with the time of disintegration in a linear mode. The plasma 
levels of the drug and metabolite as well as their cumulative urinary recovery were relatively low with 
respect to those reported when 5-ASA is delivered to the small bowel. 
 20 
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1. INTRODUCTION 
5-aminosalicylic acid (5-ASA), also known as mesalazine or mesalamine, is the first-line and most 
widely used treatment for remission and maintenance of remission of mild-to-moderate ulcerative 
colitis (UC) (Feagan, 2003; Ham and Moss, 2012; Sandborn, 2008). UC is a potentially debilitating 
chronic inflammatory pathology that, together with Crohn's disease, affects over three million people in 5 
Europe and North America, showing a currently increasing trend in developing countries of non-
Western areas (Molodecky et al., 2012; Ng et al., 2017). 
Because it has been proved to act locally, selective delivery of 5-ASA to the disease site, via oral or 
rectal administration, is generally pursued (Friend, 2005; Perrotta et al., 2015). This enhances the 
efficacy and tolerability associated with the therapy, by increasing the dose fraction reaching the 10 
inflamed mucosa and reducing that entering the systemic circulation due to poor colonic absorption  
In order to obtain effective levels of 5-ASA in the large bowel following oral intake, proper delivery 
strategies need to be used (Karrout et al., 2015; Qureshi and Cohen, 2005; Sardo et al., 2019). The vast 
majority of commercially-available 5-ASA products relate to a pH-dependent strategy (Maroni et al., 
2017b; Sandborn and Hanauer, 2003). The basic concept behind that is the aboral increase in the 15 
gastrointestinal pH, which ranges from acidic values of the gastric fluid to neutral or slightly alkaline 
ones of the distal intestine contents. Accordingly, coated dosage forms provided with an enteric film 
are used, and polymers soluble at pH > 6.0 or 7.0, primarily polymethacrylates such as Eudragit
®
 S and 
Eudragit
®
 L, are generally employed as the coating agents (Maroni et al., 2013b; Palugan et al., 2015). 
Nevertheless, it has broadly been highlighted that these coatings may not be suitable for site-selective 20 
release to the colon (Ashford et al., 1993; Ibekwe et al., 2008, 2006). Indeed, while the dissolution pH 
threshold of such polymers can physiologically be exceeded in the small intestine, it may fail to be 
reached in the proximal colon, where acidic values are often encountered particularly in active phases 
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of UC (Fallingborg et al., 1993; Nugent et al., 2001). Moreover, there is large intra- and inter-patient 
variability in the intestinal pH profile. Therefore, the likelihood of both premature release and of 
release failure is to be accounted for. In the lack of effective and reliable targeting, mucosal levels of 5-
ASA may vary, thus affecting the clinical response rate (Klotz and Schwab, 2005). 
Although no related drug products are found on the marketplace, colon delivery approaches that 5 
leverage physiological parameters other than the luminal pH have been proposed and extensively 
studied (Gazzaniga et al., 1994; McConnell et al., 2009; Pinto, 2010; Wolk et al., 2013). Among these, 
the time-dependent strategy exploits the small intestinal transit time (SITT) (Davis, 1985; Gazzaniga et 
al., 2006). It has been shown that SITT has duration of 3±1 h (mean±sd) and is relatively little 
influenced by variables such as the fasted/fed state of subjects, the kind of dosage forms and, in the 10 
case of solids, the size and density of the latter. In addition, because it is no inherent physiological 
characteristic of the colonic region, SITT would to a lesser extent undergo pathological alterations 
associated with UC as compared with the local pH and the composition of the microbiota (Bak et al., 
2018) . 
Time-dependent delivery systems are generally coated dosage forms, wherein a pH-independent 15 
coating material is responsible for a programmable lag phase prior to release (Gazzaniga et al., 2006; 
Maroni et al., 2013b). In order to turn time-programmed into site-selective release, the impact of 
unpredictable gastric residence time is to be overcome, which is commonly accomplished through the 
use of a gastroresistant outer coating. Furthermore, the lag phase needs to be sufficiently extended to 
cover the whole small intestinal transit. Taking account of the generally long-lasting transit of dosage 20 
forms in the large intestine, lag phases of 6 to 7 h may reasonably prevent early drug release into the 
proximal gastrointestinal tract while still allowing for targeted delivery to the ascending colon (Wilson, 
2010). According to the nature of the inner coating polymer and the formulation of the core, the drug 
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release may be deferred through a range of mechanisms (Maroni et al., 2013c). When swellable 
hydrophilic polymers, typically soluble cellulose derivatives, are used as coating agents, release is 
delayed due to their slow interaction with the aqueous gastrointestinal fluids and consequent 
dissolution and/or erosion in the hydrated state (Maroni et al., 2016b). 
A previously described delivery system, provided with a functional low-viscosity HPMC layer applied 5 
by spray-coating, has been proved to fulfill the desired release behavior in vitro and in vivo, with lag 
phases increasing in duration as a function of the thickness of such a layer (Sangalli et al., 2001; Zema 
et al., 2007). Moreover, colonic breakup was highlighted by γ-scintigraphy following administration of 
placebo units to healthy volunteers. Various configurations of this delivery platform were proposed by 
using different cores (Del Curto et al., 2014, 2011, 2009; Maroni et al., 2013a) and alternative 10 
manufacturing techniques (Macchi et al., 2015; Foppoli et al., 2017; Melocchi et al., 2018; Sangalli et 
al., 2009; Zema et al., 2013). Particularly, in the form of coated insulin minitablets, the system brought 
about more than two-fold bioavailability and ten-fold pharmacological availability vs a reference 
uncoated formulation for immediate release when administered to diabetic rats (Maroni et al., 2016a). 
Based on the current need for effectively targeted pharmacological therapy of IBD, the aim of the 15 
present study was to manufacture, according to the above-mentioned delivery technology, an oral 
system for colonic release of 5-ASA, and to evaluate the relevant in vitro as well as in vivo 
performance. The manufacturing step involved (i) preparation of immediate-release tablet cores 
containing 400 mg of the drug, (ii) application of a low-viscosity HPMC layer of approximately 750 
µm in thickness, by virtue of previous in vivo studies of analogous systems (Maroni et al., 2016a; 20 
Sangalli et al., 2009, 2001), and (iii) enteric coating of the HPMC-coated units. After physico-
technological and in vitro release characterization, combined pharmacokinetic and scintigraphic 
investigation into the performance of the final delivery system was carried out in healthy volunteers. 
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2. MATERIALS AND METHODS 
2.1. MATERIALS 
5-aminosalcylic acid (5-ASA, Chemi, I), povidone (Kollidon
®
25 BASF, D) and crospovidone 
Kollidon
®
 CL, BASF, D), glyceryl dibehenate (Compritol
®
888 ATO, Gattefossé, F), lactose 
(Pharmatose DCL11 DMW, NL), samarium oxide (Sigma-Aldrich, US), hydroxypropyl 5 
methylcellulose (HPMC, Methocel
®
 E50, Colorcon, US; MW 65-80 kDa), polyethylene glycol (PEG 
6000, Hoechst, UK), poly(methacrylic acid, methyl methacrylate) 1:1  copolymer (Eudragit
®
 L30D, 
Evonik, D), triacetin and talc (Tradeco, I). 
 
2.2. METHODS 10 
2.2.1. Manufacturing and physico-technological characterization of the 5-ASA delivery system 
1.5 l of povidone aqueous solution (10% w/v) was slowly added to 1.6 kg of 5-ASA powder and 
kneaded in a high shear mixer at 100 rpm for 5 min (Roto Junior 10L Zanchetta-Romaco, I). The wet 
mass was forced through a 250 µm net sieve of an oscillating granulator (AR400 Erweka, D).  The 
resulting granules were oven-dried at 40 °C for 20 h and sieve-calibrated (500 µm). 0.396 kg of 15 
lactose, 0.072 kg of crospovidone, 0.032 kg of talc, 0.032 kg of glyceryl behenate, and 0.040 kg of 
samarium dioxide were added and mixed in a V-blender (Erweka, D). The mixture was tableted by a 
rotary machine (AR 13 Ronchi, I; concave punches diameter 11 mm, curvature radius 9 mm) set to 
provide adequate mechanical characteristics of the cores, so that these could withstand the subsequent 
coating steps while maintaining prompt disintegration properties upon exposure to aqueous media. 20 
Tablets were checked for weight (n=20), height and diameter (digital micrometer Mitutoyo, J; n=20), 
crushing strength (crushing tester TBH30 Erweka, D; n=10), friability (friabilometer TA3R Erweka, D) 
and disintegration time (three-position disintegration apparatus Advanced Products, I; n=6). The 
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weight, height, diameter, crushing strength, friability and disintegration time were 555.2±2.8 mg, 
6.453±0.037 mm, 11.072±0.004 mm, 81±19 N, <1 % and <1 min, respectively. 
The 5-ASA tablet cores were coated in fluid bed equipment (Uniglatt, Glatt, D) using an aqueous 
solution of Methocel
®
 E50 (7.5% w/v) and PEG 6000 (0.5% w/v) under the following process 
conditions: batch size 1 kg, inlet air temperature 60-64 °C, outlet air temperature 39-44 °C, nebulizing 5 
air pressure 3.5 bar, nozzle port size 1.2 mm. The coating level was monitored by measuring the 
weight and height as well as diameter (digital micrometer) of samples (n=10) collected at successive 
time points. The coating thickness was calculated as half of the mean difference between the height 
and diameter of coated units and cores, respectively.  
Coated systems having selected weight gains, in a 10-50% range (M10, M20, M30, M40 and M50), 10 
were cross-sectioned and the thickness of the applied layer was measured on images acquired by digital 
microscope (Dyno-Lite Pro AM-413T, AnMo Electronics Co., TW). Thickness data were the mean of 
measurements performed in 8 different regions of the HPMC layer of each of 3 coated units. 
Enteric coating dispersions (Eudragit
® 
L30D 35% w/v; Triacetin 3% w/v, Talc 7% w/v, deionized 
water 55 w/v) were applied onto HPMC-coated cores having nominal 50% weight gain to give final 15 
gastroresistant systems (GM50). The coating process was run up to approximately 3% weight gain 
using the same fluid bed apparatus under the following conditions: batch size 1 kg, inlet air 
temperature 60-62 °C, outlet air temperature 39-41 °C, nebulizing air pressure 1.5 bar, nozzle port size 
1.2 mm. Mass uniformity of the final double-coated system was assessed (CV=0.58).  
SEM photomicrographs of cross-sectioned final double-coated units were taken and used to assess the 20 
thickness of the enteric coating and confirm that of the HPMC layer. Samples were gold sputtered 
using a plasma evaporator under vacuum, and photomicrographs were acquired at an accelerated 
voltage of 10 kV at different magnifications (Leo 1430, Carl Zeiss, CH). 
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2.2.2. In vitro evaluation 
For release testing, a three-position disintegration apparatus was used in place of a dissolution 
equipment to avoid adhesion of swollen HPMC layer of the coated system to the vessels, which would 
impact on data reliability (Zema et al., 2007). Each unit was inserted into a basket-rack assembly so 5 
that only one of the 6 available tubes was occupied. The basket-rack assemblies moved in separate 
vessels at a constant 29 to 32 cycles/min frequency through a 55±2 mm distance, immersed in 800 ml 
of fluid at 37±1 °C, i.e. hydrochloric acid solution pH 1.2 for 2 h (gastroresistant systems only) and/or 
phosphate buffer pH 6.8. 
Fluid samples were withdrawn continually for spectrophotometrical assay (λ=244 nm) at fixed time 10 
points and subsequently reintroduced into the vessel. Release tests (n=3) were carried out under sink 
conditions, here meant as those at which the concentration of the drug was <20% of its solubility in 
phosphate buffer pH 6.8 at 37 °C (~3.5 g/l) (Karkossa and Klein, 2018).  
In vitro lag time was expressed as the time required for 10% drug release in phosphate buffer pH 6.8 
(t10%) and calculated by linear interpolation of the experimental data immediately before and after this 15 
release percentage. 
 
2.2.3. Pharmacoscintigraphic evaluation  
The in vivo evaluation was carried out as an open-label, single-dose study in 6 healthy male Caucasian 
volunteers aged 18 to 45 years, who received the test formulation (GM50) in fasted and fed conditions 20 
according to a randomized two-period crossover design (washout of 7 days). The investigation was 
undertaken at the U.L.B., Faculté de Médecine, Hôpital Erasme, Service des Radioisotopes (Brussels, 
BE). The protocol was granted approval by a registered ethics committee, in compliance with local 
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regulations. The study was performed in accordance with the Declaration of Helsinki and its 
subsequent revisions. The enrolled subjects gave written informed consent and, prior to beginning, 
underwent a thorough medical examination. These controls were repeated at discharge. No medications 
were allowed during the study period. 
Formulation GM50 was irradiated in a neutron flux of 2·10
12
 cm
-2
/s
 
for 4 min, so that the stable isotope 5 
152
Sm could be converted into the γ-emitting radionuclide 153Sm (Wilding et al., 2001). Release testing 
after neutron irradiation confirmed that no alterations were brought about by such a procedure. At the 
time of dosing, the formulation was radiolabelled with 3.0 MBq. For each study session, 1.85 MBq 
99m
Tc-colloid in 100 ml of water was also administered to outline the gastrointestinal tract. 
On each administration day, at 8.00 a.m., all volunteers took orally a single dose of the radiolabeled 10 
formulation with 100 ml of tap water at room temperature. In the fed administration regimen, a 
standard breakfast of same composition was served 30 min before intake. Standard lunch, snack and 
dinner were served to all volunteers at 4, 8 and 12 h post-dose, respectively. At 24 h post-dose, 
breakfast was allowed as prescribed in the balanced standard diet the volunteers had to follow in the 3 
days preceding administration. Neither food nor drink apart from these meals were permitted (except 15 
for water).  
The subjects were placed in supine position under the collimator of the γ-camera, and images of 2 min 
in duration were acquired just before intake (t=0) and at the scheduled time points of 0.5, 1, 1.5, 2, 2.5, 
3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 24 h post-dose. Actual imaging times are reported in the Results and 
Discussion section. Gastric emptying time (GE), colon arrival time (CA), small intestinal transit time 20 
(SITT) and time of disintegration (td) as well as site of disintegration (sd), i.e. when and where 
dispersed fragments from disintegrated units were first observed, respectively, were assessed. Time of 
disintegration after gastric emptying (td-GE) was calculated by subtracting GE from td.  
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Blood sampling was scheduled just before intake of the dosage form (t=0), every hour up to 12 h and at 
24 h post-dose. Actual sampling times are reported in the Results and Discussion section. Urine was 
also collected prior to administration, from 0 to 12 h and from 12 to 24 h. 5-ASA and its metabolite N-
acetyl 5-ASA (Ac5-ASA) were assayed in the plasma and urine by a HPLC validated method with 
fluorescence detection adapted from (Fischer et al., 1981). The limit of quantitation, defined as the 5 
analyte concentration that provides a relative response with a coefficient of variation not exceeding 20, 
was 5 ng/ml for both 5-ASA and Ac5-ASA in the plasma, and, in urine, 0.25 µg/ml for 5-ASA and 5 
µg/ml for Ac5-ASA. 
Lag time prior to appearance of the drug (tlag5-ASA) and of the metabolite (tlagAc5-ASA) in the bloodstream 
was expressed as the time at which 5-ASA and Ac5-ASA were first assayed in the plasma. 10 
 
 
3. RESULTS AND DISCUSSION 
3.1. IN VITRO EVALUATION 
Tablet cores containing 5-ASA underwent aqueous spray-coating with low-viscosity HPMC as 15 
previously described, in order to obtain a lag phase prior to release, according to the time-dependent 
approach to colon delivery (Sangalli et al., 2001). The operating parameters were preliminarily set up, 
and slight adjustments were progressively required due to the growing mass of the substrate. Coated 
formulations having nominal 10, 20, 30, 40 and 50 % weight gain (codes M10, M20, M30, M40 and 
M50) were subjected to physico-technological and release characterization. Consistent weight and 20 
coating thickness as well as a smooth surface were observed (Table I, Figures 1 and 2). A linear 
correlation (R
2
=0.9973) was found between the weight gain of the units and the thickness of the 
HPMC layer (Figure 3). The pursued nominal thickness of 750 µm corresponded to a weight gain of 
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approximately 50%. The coated systems, subjected to crushing test, were deformed without breaking at 
applied forces up to 300 N. Only in the case of M10, signs of rupture were noticed. 
The release profiles from uncoated cores and HPMC-coated units, obtained in phosphate buffer pH 6.8 
under sink conditions, are reported in Figure 4. A lag phase preceded the onset of 5-ASA release in all 
cases. By increasing the coating level, the duration of the lag phase was extended. A slow release phase 5 
due to outward drug diffusion was especially evident in the case of formulations having the greater 
weight gain (M40 and M50). Afterwards, release was prompt and quantitative, associated with the 
observed breakup of the swollen polymer layer. The relationship between the coating thickness and the 
duration of the lag phase, expressed as t10%, was found linear (Figure 5). This finding was consistent 
with previous ones relevant to coated systems having tableted cores of smaller size, cores of different 10 
nature (hard and soft gelatin capsules) or functional polymeric layers fabricated by different techniques 
(injection-molding, fused deposition modelling) (Gazzaniga et al., 2011; Maroni et al., 2017a; Sangalli 
et al., 2009). 
Formulation M50, having coating thickness of approximately 765 µm (~68 mg/cm
2
), was thus 
provided with an enteric film intended to prevent interaction of the HPMC layer with the aqueous fluid 15 
in the stomach, thus overcoming the influence of highly variable gastric residence time on the intestinal 
site of release. Application of the enteric soluble polymer led to an increase in thickness of 
approximately 60 µm (~4.5 mg/cm
2
) in the final double-coated system (GM50). Evaluated for release 
according to the compendial two-stage testing procedure, the gastroresistant units were proved to 
withstand 2 h in HCl solution. The release pattern observed after switching to phosphate buffer pH 6.8 20 
was consistent with that shown by the corresponding non-gastroresistant formulation, with non-
significantly different t10% (p=0.79) (Figure 6). Enteric coating was thus demonstrated not to impact on 
the performance of the HPMC layer. 
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3.2. IN VIVO EVALUATION 
A pharmacoscintigraphic investigation was undertaken in 6 healthy male volunteers, under fasted and 
fed conditions. γ-scintigraphy was used to study the transit of the administered dosage forms (GM50) 
throughout the gastrointestinal tract and the site as well as time of relevant breakup. Moreover, 5-ASA 5 
and its N-acetyl derivative, resulting from intestinal and hepatic metabolism, were assayed in plasma 
samples collected within the imaging time frame in order to concurrently monitor their concentration in 
the systemic circulation (De Vos, 2000; Goebell et al., 1993; Klotz and Schwab, 2005). Cumulative 
urinary recovery of both compounds was also assessed.  
All volunteers concluded the trial without any remarkable side effect or alteration in the main clinical 10 
parameters that could be related to the treatment. Pharmacoscintigraphic results are presented in Tables 
II and III as well as in Figures 7 and 8. Horizontal bars are superimposed to concentration vs time 
curves of 5-ASA and Ac5-ASA to highlight concomitant position and disintegration of the units within 
the gastrointestinal tract. 
A lag phase followed by appearance of the drug and its metabolite in the plasma was in all cases 15 
observed. As expected, 5-ASA levels turned out far lower than Ac5-ASA ones (Bondesen et al., 1988; 
Goebell et al., 1993). Overall, the concentrations of the drug and metabolite pointed out poor 
absorption, possibly consistent with distal intestinal release (Bondesen et al., 1988; Myers et al., 1987). 
This was in line with cumulative urinary recovery of 5-ASA and Ac5-ASA, which never exceeded 
20% of the administered dose. 20 
Gastric residence was variable in duration, being generally shorter in the fasted regimen (p < 0.05). 
Both in fasted and fed subjects, average SITT was in good agreement with previous findings, which the 
time-dependent colon delivery approach relies on [21,46]. Colon arrival was always within 5 h post-
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dose. Notably, in no cases disintegration occurred before the units had entered the large bowel, and 
residual radioactivity, ranging from 10 to 100%, was still observed in the colon at 24 h after intake. 
In 8 cases out of 12, disintegration of the units and appearance of 5-ASA and/or Ac5-ASA took place 
within 12 h after administration, the metabolite being detected either earlier than the parent drug or at 
the same time point. In those 8 cases, the time at which disintegration was first observed after gastric 5 
emptying (td-GE) turned out to be 8.73±2.85 h and 7.77±3.10 h for fasted and fed subjects, respectively, 
indicating no major influence of food intake (p=0.66). The site of disintegration (sd), i.e. where 
dispersed fragments from disintegrated units were evident for the first time, was the caecum in one 
case (2Fa), the ascending colon in 5 cases (3Fa, 4Fa, 2Fe, 3Fe, 4Fe) and the transverse colon in the 
remaining 2 cases (1Fa, 6Fe). The time of disintegration (td), i.e. when the dispersed fragments were 10 
first seen, followed (1Fa, 3Fa, 4Fa, 2Fe, 3Fe, 4Fe, 6Fe) or coincided with (2Fa) the time at which Ac5-
ASA was first assayed in the plasma (tlagAc5-ASA), the metabolite being detected generally earlier than 
the parent drug because of its higher concentration. Diffusion of 5-ASA through the swollen 
hydrophilic polymer coating may thus have taken place before breakup of the units. The time elapsing 
from the detection of Ac5-ASA in the plasma to that of dispersed fragments in the intestine, i.e. the 15 
difference between tlagAc5-ASA and td, was 0.81±0.56 h in fasted subjects and 1.27±0.59 h in fed ones. A 
good linear correlation was found between tlagAc5-ASA and td in both fasted and fed regimens, with the 
slope of regression lines reflecting the occurrence of metabolite absorption prior to breakup of the units 
(Figure 9). 
In those 4 cases where disintegration was not observed within 12 h after intake (5Fa, 6Fa, 1Fe, 5Fe), a 20 
comprehensive evaluation of the performance of the dosage form was hindered by the lack of 
information between 12 h and 24 h, time interval during which neither imaging nor blood sampling 
were scheduled. These specific cases are discussed into detail as follows.  
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In subject 6Fa, 5-ASA and Ac5-ASA appeared in the plasma 11.2 h after intake, while disintegration 
was not seen in the images taken up to 12 h. Fragments from the disintegrated unit were observed at 24
 
h post-dose in the transverse and descending colon, and residual radioactivity was 83%. The plasma 
concentrations of drug and metabolite, along with their overall cumulative urinary recovery, were of 
such an extent as to indicate that breakup would have occurred within the “blind” time lapse well 5 
before the 24th hour post-dose. Through the linear relationship presented in Figure 9, breakup was 
estimated at 12.55 h. Based on colon arrival time, this would reasonably be consistent with the unit 
being positioned in the ascending and/or transverse colon.  
Analogous considerations can be drawn from scintigraphic and pharmacokinetic data relevant to 
subject 5Fe. In this case, td was estimated at 13.87 h. At 24 h post-dose, radioactivity in the transverse 10 
and descending colon was still 100%. 
In the same subject under fasted condition (5Fa), plasma levels of drug and metabolite as well as the 
disintegrated unit were detected at 24th hour only, fragments of the dosage form being positioned in 
the transverse and descending colon. Therefore, estimation of td based on the linear regression model 
was not possible in this instance, and no hypothesis could accordingly be made about the site of 15 
disintegration. However, plasma concentrations and urinary recovery of 5-ASA and Ac5-ASA, 
relatively high and comparable with data from the same subject in the fed state, suggest breakup of the 
unit should be traced back to several hours before the last sampling time at 24 h after intake.  
In subject 1Fe, only very low 5-ASA and Ac5-ASA plasma levels, and as little as 10% of residual 
radioactivity in the distal part of the descending colon, were found at 24 h. By the same time, neither 20 
the drug nor the metabolite was recovered in the urine. These results would indicate that breakup 
occurred just before the last time point and the unit was voided soon after disintegration. 
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Overall, the administered dosage forms disintegrated and released their drug load in the large intestine, 
under both fasted and fed conditions of the subjects participating in the study. 
 
 
 5 
4. CONCLUSIONS 
In the present work, an oral 5-ASA delivery system aimed at time-dependent colonic release was 
manufactured and evaluated in vitro as well as in healthy volunteers, by γ-scintigraphy and 
pharmacokinetics techniques. The system encompassed an immediate-release drug-containing tablet 
core, a low-viscosity HPMC layer deferring the onset of release and an enteric outer coating protecting 10 
the inner formulation from contact with gastric fluid during poorly predictable stomach residence. 
The expected in vitro performance was confirmed, with lag time extended as a function of the HPMC 
coating level. A phase of diffusive release of a relatively small percentage of the drug appeared with 
increasing coating thickness. 
The imaging study showed that disintegration of the administered units was in no cases observed prior 15 
to colon arrival. Breakup mainly occurred in the caecum, ascending or transverse colon. Notably, the 
small intestinal transit time was proved fairly reproducible and consistent with the tenets of the time-
dependent formulation strategy. These findings were independent of the fasted or fed dosing regimen. 
A lag phase following administration always preceded the appearance of the drug and its main 
metabolite in the bloodstream. An agreement was found between this lag time and the onset of 20 
disintegration of the units. 5-ASA and Ac5-ASA were generally detected approximately 1 h before 
breakup could be observed, which may reflect the diffusive release phase noticed in the in vitro study. 
After the lag phase, the concentrations of drug and metabolite reached in the plasma were relatively 
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low as compared with data obtained following delivery of the drug to more proximal regions of the gut. 
This was consistent with the mean cumulative urinary recovery of 5-ASA and Ac5-ASA over 24 h that 
was below 10% of the drug dosed. 
On average, the time taken for the dosage form to disintegrate after emptying from the stomach, where 
swelling of the functional HPMC coating was prevented by the gastroresistant film, turned out slightly 5 
longer than should in principle be pursued according to the time-dependent colon delivery approach. 
However, the results obtained were mostly satisfactory in terms of large intestinal targeting. Therefore, 
though with due caution in view of the need for avoiding early release into the small bowel, 
formulation changes could be implemented to possibly shorten the in vivo lag time, thus offering better 
chances of drug delivery into the proximal colon and reducing the risk of release failure. 10 
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FIGURE CAPTIONS 
 
Fig. 1. Photographs of uncoated cores and HPMC-coated systems having increasing coating level.  
 
Fig. 2. SEM photomicrograph of the cross-section of a final double-coated system (GM50).  5 
  
Fig. 3. Relationship between weight gain and HPMC coating thickness. 
 
Fig. 4. Release profiles of 5-ASA from uncoated cores and HPMC-coated systems having increasing 
coating level (phosphate buffer pH 6.8). 10 
 
 
Fig. 5. Relationship between HPMC coating thickness and 5-ASA in vitro lag time (t10%). 
 
Fig. 6. Release profile of 5-ASA from the final double-coated system (GM50). 15 
 
Fig. 7. 5-ASA (□) and Ac5-ASA (Δ) plasma concentrations vs time profiles following administration of 
the final double-coated system (GM50) to fasted volunteers (the dashed portion of the curves indicates 
the 12-24 h time frame during which no experimental data were collected and does not reflect the actual 
time course of concentration).  Red, yellow and green bars (bottom) indicate gastric, small intestinal 20 
and colonic residence, respectively; the blue bar (top) indicates disintegration.  
 
Fig. 8. 5-ASA (□) and Ac5-ASA (Δ) plasma concentrations vs time profiles following administration of 
the final double-coated system (GM50) to fed volunteers (the dashed portion of the curves indicates the 
24 
 
12-24 h time frame during which no experimental data were collected and does not reflect the actual 
time course of concentration). Red, yellow and green lines (bottom) indicate gastric, small intestinal 
and colonic residence, respectively; the blue line (top) indicates disintegration. 
 
Fig. 9. Relationship between Ac5-ASA in vivo lag time (tlagAc5-ASA) and time of disintegration (td). 5 
 
 
Table I. Weight, weight gain and coating thickness data relevant to uncoated cores and HPMC-coated 
systems  
 
 
 
 
 
 
 
 
*measured by digital microscope   
 
 
 
 
  
Formulation 
Weight (mg) 
Mean±sd  
Weight gain (%) 
Coating thickness
*
 (µm) 
Mean±sd 
Uncoated core 555.2±2.8 - - 
M10 615.2±5.4 10.8 159.5±17.6 
M20 669.0±5.8 20.5 306.8±33.1 
M30 720.1±5.3 29.7 453.4±35.6 
M40 782.8±5.0 41.0 633.9±31.5 
M50 838.5±4.7 51.0 764.8±33.4 
Table(s)
Table II. Scintigraphic data under fasted and fed conditions   
FASTED CONDITION  
Subject  
Gastric 
emptying 
time           
GE (h) 
Small 
intestinal 
transit time 
SITT (h) 
Colon 
arrival time              
CA (h) 
  Time of 
disintegration 
td (h) 
Time of 
disintegration after 
gastric emptying   
td-GE (h) 
  Site of 
disintegration 
sd 
1 1.75 3.00 4.75 12.00 10.25 TC 
2 0.33 4.50 4.83   4.83   4.50 C 
3 0.42 1.50 1.92 11.00 10.58 AC 
4 0.42 4.58 5.00 10.00   9.58 AC 
5 0.58 4.50 5.08 # # # 
6 0.58 1.59 2.17        # (12.55)         # (11.97) # 
Mean 0.68 3.28 3.96   9.46   8.73  
sd 0.53 1.47 1.49   3.19   2.85  
 
FED CONDITION 
Subject  
Gastric 
emptying 
time           
GE (h) 
Small 
intestinal 
transit time 
SITT (h) 
Colon 
arrival time              
CA (h) 
  Time of 
disintegration 
td (h) 
Time of 
disintegration after 
gastric emptying            
td-GE (h) 
  Site of 
disintegration 
sd 
1 1.83 1.92 3.75 # # # 
2 2.33 2.50 4.83   5.83   3.50 AC 
3 1.41 3.51 4.92   8.92   7.51 AC 
4 2.50 2.50 5.00 12.90 10.40 AC 
5 1.92 3.00 4.92        # (13.87)         # (11.95) # 
6 0.58 3.59 4.17 10.25   9.67 TC 
Mean 1.76 2.84 4.60   9.48   7.77  
sd 0.70 0.65 0.51   2.94   3.10  
Caecum (C), ascending colon (AC), transverse colon (TC). 
Time (td) and site (sd) of disintegration refer to when and where dispersed fragments of units were first observed 
# Definite time and anatomical position of disintegration could not experimentally be assessed since dispersed fragments were seen at 24 h only. 
Disintegration occurred between 12 and 24 h in the colon. Times of disintegration that could be estimated on the basis of the correlation in Figure 9 
are in brackets.  
 
 
 
 
  
Table III. Pharmacokinetic data under fasted and fed conditions 
FASTED CONDITION 
Subject  
5-ASA      
lag time      
tlag5-ASA (h) 
Ac5-ASA    
lag time                         
tlagAc5-ASA (h) 
5-ASA cumulative 
urinary recovery (mg) 
Ac5-ASA cumulative 
urinary recovery (mg) 
0-12 h 0-24 h 0-12 h 0-24 h 
1 11.70 10.70 0.00 0.64 0.00 29.36 
2   5.83   4.83 0.87 2.58 24.75 83.63 
3 11.00 10.00 0.00 0.69 0.00 17.77 
4 11.00   9.07 0.00 0.68 0.00 19.04 
5 § § 0.00 1.62 0.00 34.02 
6 11.20 11.20 0.00 1.12 0.00 25.18 
Mean 10.15   9.16 0.15 1.22 4.13 34.83 
sd   2.43   2.55 0.36 0.77 10.10 24.68 
 
FED CONDITION 
Subject  
5-ASA      
lag time      
tlag5-ASA (h) 
Ac5-ASA    
lag time                         
tlagAc5-ASA (h) 
5-ASA cumulative 
urinary recovery (mg) 
Ac5-ASA cumulative 
urinary recovery (mg) 
0-12 h 0-24 h 0-12 h 0-24 h 
1 § § 0.00 0.00  0.00   0.00 
2   5.20   5.20 0.00 0.59 25.99 47.99 
3   8.03   7.30 0.35 0.65   6.57 14.72 
4 12.10 11.00 0.00 1.19   0.00 27.45 
5 12.00 12.00 0.00 1.15   0.00 26.56 
6   9.32   9.32 0.00 1.67   0.00  68.5 
Mean   9.33   8.96 0.06 0.88   5.43 30.87 
sd   2.90   2.76 0.14 0.58 10.41 24.30 
 
§ Definite time of appearance of 5-ASA and Ac5-ASA in plasma could not experimentally be assessed since these were assayed at 24 h only. The 
appearance of drug and metabolite occurred between 12 and 24 h.  
 
  
 Fig. 1. Photographs of uncoated cores and HPMC-coated systems having increasing coating level 
(ruler scale in cm).  
 
 
Figure 1 Foppoli et al revised
  
Fig. 2. SEM photomicrograph of the cross-section of a final double-coated system (GM50).  
 
 
  
 
Figure 2 Foppoli et al revised
  
Fig. 3. Relationship between weight gain and HPMC coating thickness. 
 
Figure 3, Foppoli et al
 Fig. 4. Release profiles of 5-ASA from uncoated cores and HPMC-coated systems having 
increasing coating level (phosphate buffer pH 6.8). 
 
Figure 4 Foppoli et al
 Fig. 5. Relationship between HPMC coating thickness and 5-ASA in vitro lag time (t10%). 
 
Figure 5, Foppoli et al
 Fig. 6. Release profile of 5-ASA from the final double-coated system (GM50). 
 
Figure 6 Foppoli et al revised
Fig. 7. 5-ASA (□) and Ac5-ASA (Δ) plasma concentrations vs time profiles following 
administration of the final double-coated system (GM50) to fasted volunteers (the dashed portion of 
the curves indicates the 12-24 h time frame during which no experimental data were collected and 
does not reflect the actual time course of concentration).  Red, yellow and green bars (bottom) 
indicate gastric, small intestinal and colonic residence, respectively; the blue bar (top) indicates 
disintegration.  
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Figure 7 Foppoli et al revised
  
 
Fig. 8. 5-ASA (□) and Ac5-ASA (Δ) plasma concentrations vs time profiles following 
administration of the final double-coated system (GM50) to fed volunteers (the dashed portion of 
the curves indicates the 12-24 h time frame during which no experimental data were collected and 
does not reflect the actual time course of concentration). Red, yellow and green lines (bottom) 
indicate gastric, small intestinal and colonic residence, respectively; the blue line (top) indicates 
disintegration. 
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Fig. 9. Relationship between Ac5-ASA in vivo lag time (tlagAc5-ASA) and time of disintegration (td). 
Figure 9 Foppoli et
